![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » LumiraDx Rapid COVID-19 Test Authorized for Emergency Use
LumiraDx Rapid COVID-19 Test Authorized for Emergency Use
![LumiradxLogo.png](https://www.fdanews.com/ext/resources/test/Device_Images6/LumiradxLogo.png?t=1597975244&width=430)
The FDA has granted an Emergency Use Authorization (EUA) for LumiraDx’s rapid SARS-CoV-2 assay.
The EUA limits the assay’s use to certified laboratories that use the Massachusetts company’s LumiraDx testing platform. The test uses nasal swabs from suspected COVID-19 patients within the first 12 days of symptom onset to detect the presence of viral antigens.
The company said it plans to produce 2 million tests in September, increasing to 10 million tests in December.
Upcoming Events
-
21Oct